M J Beard1, Z Jeewa, S Bashir, R Cardigan, S Thomas. 1. Components Development, NHS Blood and Transplant, Crescent Drive, Brentwood, Essex, UK. martin.beard@nhsbt.nhs.uk
Abstract
BACKGROUND AND OBJECTIVES: The ADVIA 2120 Haematology Analyser is capable of measuring parameters that can be used as markers of platelet activation, mean platelet component (MPC), platelet component distribution width (PCDW) and mean platelet mass (MPM). This study investigated the degree of correlation of these measures of platelet granularity with CD62P measurement of platelet activation by flow cytometry in platelet concentrates. MATERIALS AND METHODS: Pooled platelets in plasma/citrate phosphate dextrose (CPD) anticoagulant or apheresis platelets in plasma/acid citrate dextrose formula A (ACD-A) anticoagulant were evaluated. Pooled platelets were tested during 13 day storage, and apheresis platelets within 24 h of venepuncture. These were assessed for platelet activation using CD62P and the ADVIA, with or without extra EDTA anticoagulant. RESULTS: In pooled platelets, PCDW correlated strongly with CD62P, both with and without the addition of extra EDTA anticoagulant. There was a good correlation between MPC and CD62P with additional EDTA, but a weaker correlation without extra EDTA. There was no correlation between CD62P and MPM. In apheresis platelets the correlation between PCDW and CD62P was poor, whereas MPC correlated strongly with CD62P if EDTA anticoagulant was added. CONCLUSION: The usefulness of ADVIA platelet granularity measures to predict the degree of platelet activation depends upon the anticoagulant present in the platelet concentrate, and whether extra EDTA is added to the sample. Although ADVIA MPC and PCDW measurement could not replace CD62P or other gold standard methods of assessing platelet activation, these ADVIA 2120 parameters may provide a quick check of platelet concentrate quality.
BACKGROUND AND OBJECTIVES: The ADVIA 2120 Haematology Analyser is capable of measuring parameters that can be used as markers of platelet activation, mean platelet component (MPC), platelet component distribution width (PCDW) and mean platelet mass (MPM). This study investigated the degree of correlation of these measures of platelet granularity with CD62P measurement of platelet activation by flow cytometry in platelet concentrates. MATERIALS AND METHODS: Pooled platelets in plasma/citrate phosphate dextrose (CPD) anticoagulant or apheresis platelets in plasma/acid citrate dextrose formula A (ACD-A) anticoagulant were evaluated. Pooled platelets were tested during 13 day storage, and apheresis platelets within 24 h of venepuncture. These were assessed for platelet activation using CD62P and the ADVIA, with or without extra EDTA anticoagulant. RESULTS: In pooled platelets, PCDW correlated strongly with CD62P, both with and without the addition of extra EDTA anticoagulant. There was a good correlation between MPC and CD62P with additional EDTA, but a weaker correlation without extra EDTA. There was no correlation between CD62P and MPM. In apheresis platelets the correlation between PCDW and CD62P was poor, whereas MPC correlated strongly with CD62P if EDTA anticoagulant was added. CONCLUSION: The usefulness of ADVIA platelet granularity measures to predict the degree of platelet activation depends upon the anticoagulant present in the platelet concentrate, and whether extra EDTA is added to the sample. Although ADVIA MPC and PCDW measurement could not replace CD62P or other gold standard methods of assessing platelet activation, these ADVIA 2120 parameters may provide a quick check of platelet concentrate quality.